fingolimod hydrochloride has been researched along with Multiple Sclerosis, Chronic Progressive in 29 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 14 (48.28) | 24.3611 |
| 2020's | 15 (51.72) | 2.80 |
| Authors | Studies |
|---|---|
| Kolontareva, YM; Krasnov, VS | 1 |
| Del Giovane, C; Filippini, G; Kruja, J | 1 |
| Amato, MP; Battaglia, MA; Brambilla, L; Brescia Morra, V; Capobianco, M; Cavalla, P; Comi, G; De Luca, G; Ferraro, D; Filippi, M; Granella, F; Iaffaldano, P; Lepore, V; Lucisano, G; Lugaresi, A; Lus, G; Malucchi, S; Maniscalco, GT; Manni, A; Moiola, L; Montepietra, S; Mosconi, P; Paolicelli, D; Patti, F; Pesci, I; Petracca, M; Ponzio, M; Ragonese, P; Sola, P; Tedeschi, G; Toscano, S; Totaro, R; Trojano, M; Vianello, M | 1 |
| Dahlke, F; Häring, DA; Kappos, L; Kropshofer, H; Kuhle, J; Leppert, D; Meinert, R; Patil, A; Tomic, D | 1 |
| Apóstolos-Pereira, SL; Callegaro, D; Castrillo, BB; Silva, GD | 1 |
| Aguglia, U; Amato, MP; Angelucci, E; Boffa, G; Brescia Morra, V; Caniatti, LM; Cocco, E; Conte, A; Cottone, S; De Luca, G; Filippi, M; Galgani, S; Gasperini, C; Granella, F; Iaffaldano, P; Inglese, M; Lugaresi, A; Lus, G; Mancardi, GL; Mariottini, A; Massacesi, L; Meletti, S; Moiola, L; Nistri, R; Patti, F; Repice, AM; Romano, S; Saccardi, R; Salemi, G; Sbragia, E; Signori, A; Sola, P; Sormani, MP; Trojano, M; Zaffaroni, M | 1 |
| Everest, E; Gorkey, OD; Gulec, B; Koc, M; Saip, S; Siva, A; Tutuncu, M; Uygunoglu, U | 1 |
| Achiron, A; Angelucci, F; Halusková, S; Hartung, HP; Mareš, J; Pavelek, Z; Štourač, P; Tichá, V; Vališ, M | 1 |
| Cohen, JA; Cree, BAC; Fox, EJ; Kolodny, S; Lublin, FD; Meng, X; Williams, IM; Wolinsky, JS; Ziehn, M | 1 |
| Asseyer, S; Bäcker-Koduah, P; Berge, T; Boffa, G; Campi, C; Cellerino, M; Harbo, HF; Høgestøl, E; Inglese, M; Ivaldi, F; Kerlero de Rosbo, N; Lapucci, C; Laroni, A; Novi, G; Palmeri, S; Pardini, M; Paul, F; Piana, M; Rotta, G; Sbragia, E; Uccelli, A; Vila, G; Villoslada, P | 1 |
| Bussone, G; Louapre, C; Lubetzki, C; Maillart, E; Papeix, C; Pourcher, V; Roux, T | 1 |
| Bowen, JD; Brink, J; Brown, TR; Lucassen, EB; Repovic, P; Smoot, K; Wundes, A | 1 |
| Azimi, AR; Nourbakhsh, B; Safavi, F | 1 |
| Diaz, V; Guevara, C; Naves, R; Rosas, CS; Villa, E | 1 |
| Alvarez, E; Corboy, JR; Nair, K; Sillau, S; Vollmer, BL; Vollmer, T | 1 |
| Espinosa-Rosso, R; Gil-Bernal, R; Gómez-Gómez, C; González-Caballero, JL | 1 |
| Chataway, J; Doshi, A | 1 |
| Hentati, A; Issa, NP | 1 |
| Akiyuki, U; Kuwabara, S; Masuda, H; Masuda, S; Mori, M; Mutho, M; Tomohiko, U | 1 |
| Cree, BAC; Freedman, MS; Häring, DA; Hartung, HP; Kappos, L; Li, B; Liu, FC; Lubetzki, C; Lublin, F; Merschhemke, M; Miller, DH; Montalban, X; Putzki, N; Uitdehaag, BMJ; Weiner, H; Wolinsky, JS | 1 |
| Segal, BM; Stüve, O | 1 |
| Cohen, JA; Smith, AL | 1 |
| Ayrignac, X; Cambron, M; Carra, C; Chouraki, A; Davion, JB; Duhin, E; Labauge, P; Lacour, A; Vermersch, P | 1 |
| Dolgin, E | 1 |
| Antel, J; Blain, M; Borucki, DM; Chao, CC; de Lima, KA; Healy, L; Kenison, JE; Quintana, FJ; Rothhammer, V; Takenaka, MC; Tjon, E; Wilz, A | 1 |
| Havla, J; Hohlfeld, R; Kümpfel, T | 2 |
| Aktas, O; Boyko, A; Hartung, HP; Ingwersen, J; Kieseier, B; Kuery, P | 1 |
| Comi, G; de Vera, A; Eckert, B; Gold, S; Kappos, L; Montalban, X; O'Connor, P | 1 |
7 review(s) available for fingolimod hydrochloride and Multiple Sclerosis, Chronic Progressive
| Article | Year |
|---|---|
[Siponimod: a new view at the therapy of secondary progressive multiple sclerosis].
Topics: Azetidines; Benzyl Compounds; Fingolimod Hydrochloride; Humans; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive | 2021 |
Rituximab for people with multiple sclerosis.
Topics: Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive; Rituximab; Young Adult | 2021 |
Is there a role for off-label high-efficacy disease-modifying drugs in progressive multiple sclerosis? A network meta-analysis.
Topics: Azetidines; Benzyl Compounds; Fingolimod Hydrochloride; Humans; Immunologic Factors; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Network Meta-Analysis; Off-Label Use; Rituximab | 2022 |
The Benefits and Risks of Switching from Fingolimod to Siponimod for the Treatment of Relapsing-Remitting and Secondary Progressive Multiple Sclerosis.
Topics: Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive; Neurodegenerative Diseases; Recurrence; Risk Assessment | 2023 |
Multiple sclerosis, a treatable disease .
Topics: Adjuvants, Immunologic; Alemtuzumab; Crotonates; Demyelinating Diseases; Dimethyl Fumarate; Fingolimod Hydrochloride; Glatiramer Acetate; Glucocorticoids; Humans; Hydroxybutyrates; Immunologic Factors; Immunosuppressive Agents; Interferon beta-1a; Interferon beta-1b; Mitoxantrone; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Nitriles; Toluidines | 2017 |
Fingolimod in multiple sclerosis: mechanisms of action and clinical efficacy.
Topics: Animals; Clinical Trials as Topic; Encephalomyelitis, Autoimmune, Experimental; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis, Chronic Progressive; Propylene Glycols; Sphingosine | 2012 |
[2012: Update on diagnosis and treatment of multiple sclerosis].
Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Brain; Combined Modality Therapy; Diagnosis, Differential; Dose-Response Relationship, Drug; Drug Administration Schedule; Fingolimod Hydrochloride; Glatiramer Acetate; Glucocorticoids; Humans; Immunosuppressive Agents; Infusions, Intravenous; Interferon-beta; Methylprednisolone; Mitoxantrone; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Peptides; Plasmapheresis; Propylene Glycols; Pulse Therapy, Drug; Sphingosine; Spinal Cord | 2012 |
3 trial(s) available for fingolimod hydrochloride and Multiple Sclerosis, Chronic Progressive
| Article | Year |
|---|---|
Lymphocyte counts and infection rates: Long-term fingolimod treatment in primary progressive MS.
Topics: Adult; Double-Blind Method; Female; Fingolimod Hydrochloride; Follow-Up Studies; Humans; Immunosuppressive Agents; Infections; Lymphocyte Count; Lymphocytes; Male; Middle Aged; Multiple Sclerosis, Chronic Progressive; Time Factors | 2019 |
Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial.
Topics: Administration, Oral; Adolescent; Adult; Aged; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis, Chronic Progressive; Treatment Outcome; Young Adult | 2016 |
Oral fingolimod (FTY720) in relapsing multiple sclerosis: impact on health-related quality of life in a phase II study.
Topics: Administration, Oral; Adult; Canada; Chi-Square Distribution; Depression; Double-Blind Method; Europe; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Placebos; Propylene Glycols; Psychiatric Status Rating Scales; Quality of Life; Sphingosine; Surveys and Questionnaires; Time Factors; Treatment Outcome | 2011 |
19 other study(ies) available for fingolimod hydrochloride and Multiple Sclerosis, Chronic Progressive
| Article | Year |
|---|---|
Risk of Getting COVID-19 in People With Multiple Sclerosis: A Case-Control Study.
Topics: Adult; Age Factors; Case-Control Studies; COVID-19; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunosuppressive Agents; Interferon-beta; Italy; Male; Middle Aged; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Odds Ratio; Risk Factors; SARS-CoV-2; Severity of Illness Index; Sex Factors; Time Factors | 2022 |
Blood Neurofilament Light in Progressive Multiple Sclerosis: Post Hoc Analysis of 2 Randomized Controlled Trials.
Topics: Acute Disease; Atrophy; Biomarkers; Disease Progression; Fingolimod Hydrochloride; Humans; Intermediate Filaments; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive; Randomized Controlled Trials as Topic | 2022 |
Hematopoietic Stem Cell Transplantation in People With Active Secondary Progressive Multiple Sclerosis.
Topics: Fingolimod Hydrochloride; Glatiramer Acetate; Hematopoietic Stem Cell Transplantation; Humans; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting | 2023 |
Comparison of multiple sclerosis patients with or without rebound activity after fingolimod cessation: Five-year clinical outcomes.
Topics: Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Recurrence | 2023 |
Impact of treatment on cellular immunophenotype in MS: A cross-sectional study.
Topics: Adult; Aged; Cross-Sectional Studies; Disease Progression; Female; Fingolimod Hydrochloride; Flow Cytometry; Germany; Humans; Immunologic Factors; Immunophenotyping; Immunotherapy; Italy; Male; Middle Aged; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Norway; Spain; Young Adult | 2020 |
Patients with MS treated with immunosuppressive agents: Across the COVID-19 spectrum.
Topics: Antibodies, Monoclonal, Humanized; Betacoronavirus; Coronavirus Infections; COVID-19; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Middle Aged; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Pandemics; Pneumonia, Viral; SARS-CoV-2 | 2020 |
COVID-19 in MS: Initial observations from the Pacific Northwest.
Topics: Adult; Aged; Coronavirus Infections; COVID-19; Crotonates; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Hydroxybutyrates; Immunocompromised Host; Immunosuppressive Agents; Interferons; Lymphopenia; Male; Middle Aged; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Nitriles; Northwestern United States; Nursing Homes; Oregon; Pandemics; Pneumonia, Viral; Severity of Illness Index; Toluidines; Travel; Washington | 2020 |
B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran.
Topics: Adult; Antibodies, Monoclonal, Humanized; B-Lymphocytes; Betacoronavirus; Coronavirus Infections; Cough; COVID-19; Cross-Sectional Studies; Crotonates; Dimethyl Fumarate; Disease Susceptibility; Dyspnea; Epidemics; Female; Fever; Fingolimod Hydrochloride; Glatiramer Acetate; Hospitalization; Humans; Hydroxybutyrates; Immunocompromised Host; Immunologic Factors; Intensive Care Units; Interferons; Iran; Lung; Lymphocyte Depletion; Male; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Nitriles; Pandemics; Pneumonia, Viral; Rituximab; SARS-CoV-2; Severity of Illness Index; Toluidines; Tomography, X-Ray Computed | 2020 |
Treating patients with multiple sclerosis during the COVID-19 pandemic: Assessing the expert recommendations.
Topics: Adult; Alemtuzumab; Antibodies, Monoclonal, Humanized; Betacoronavirus; Chile; Coronavirus Infections; COVID-19; Decision Making; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Guideline Adherence; Guidelines as Topic; Health Behavior; Humans; Immunologic Factors; Interferons; Lymphocyte Count; Male; Middle Aged; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Pandemics; Pneumonia, Viral; Quarantine; SARS-CoV-2; World Health Organization; Young Adult | 2020 |
Rituximab versus natalizumab, fingolimod, and dimethyl fumarate in multiple sclerosis treatment.
Topics: Adult; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Follow-Up Studies; Humans; Immunologic Factors; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Outcome Assessment, Health Care; Recurrence; Retrospective Studies; Rituximab | 2020 |
Potential risk of disease modifying therapies on neoplasm development and coadjutant factors in multiple sclerosis outpatients.
Topics: Adult; Aged; Alemtuzumab; Crotonates; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Hydroxybutyrates; Immunosuppressive Agents; Interferon-beta; Male; Middle Aged; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Neoplasms; Nitriles; Outpatients; Proportional Hazards Models; Risk Factors; Smoking; Spain; Toluidines | 2021 |
VZV encephalitis that developed in an immunized patient during fingolimod therapy.
Topics: Encephalitis, Varicella Zoster; Female; Fingolimod Hydrochloride; Herpes Zoster Vaccine; Humans; Immunocompromised Host; Immunosuppressive Agents; Middle Aged; Multiple Sclerosis, Chronic Progressive; Propylene Glycols; Sphingosine | 2015 |
Change in vital signs after fingolimod initiation in patients with multiple sclerosis: the possible need for 24 h monitoring.
Topics: Adolescent; Adult; Drug Monitoring; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis, Chronic Progressive; Vital Signs; Young Adult | 2015 |
Primary progressive multiple sclerosis--why we are failing.
Topics: Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Multiple Sclerosis, Chronic Progressive | 2016 |
Multiple sclerosis: Fingolimod failure in progressive MS INFORMS future trials.
Topics: Clinical Trials, Phase III as Topic; Disease Progression; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multicenter Studies as Topic; Multiple Sclerosis, Chronic Progressive; Randomized Controlled Trials as Topic; Treatment Failure | 2016 |
Two cases of relapses in primary progressive multiple sclerosis after fingolimod withdrawal.
Topics: Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Chronic Progressive; Recurrence; Substance Withdrawal Syndrome | 2016 |
Therapies: Progressive steps.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antigens, CD20; Azetidines; B-Lymphocytes; Benzamides; Benzyl Compounds; Blood-Brain Barrier; Clinical Trials as Topic; Disease Progression; Dogs; Drug Approval; Fingolimod Hydrochloride; Hope; Humans; Male; Mice; Multiple Sclerosis, Chronic Progressive; Neuroprotective Agents; Piperidines; Precision Medicine; Pyridines; Rituximab; Thiazoles; Ubiquinone; United States; United States Food and Drug Administration | 2016 |
Sphingosine 1-phosphate receptor modulation suppresses pathogenic astrocyte activation and chronic progressive CNS inflammation.
Topics: Animals; Astrocytes; Cell Line, Tumor; Disease Progression; Encephalomyelitis, Autoimmune, Experimental; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Mice; Mice, Inbred C57BL; Mice, Inbred NOD; Microglia; Monocytes; Multiple Sclerosis, Chronic Progressive; Primary Cell Culture; Receptors, Lysosphingolipid; Sphingosine; Sphingosine-1-Phosphate Receptors; Transcriptome | 2017 |
[Progress of therapy in patients with multiple sclerosis].
Topics: 4-Aminopyridine; Adrenal Cortex Hormones; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Brain; Cladribine; Clinical Trials as Topic; Fingolimod Hydrochloride; Magnetic Resonance Imaging; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Propylene Glycols; Rituximab; Sphingosine | 2010 |